

AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions and listings of claims in the application.

Listing of Claims

1. (Withdrawn) A method for detecting a cancerous colon cell comprising:

contacting a sample obtained from a test colon cell with a probe for detection of a gene product of a gene differentially expressed in colon cancer, wherein the gene product is encoded by a gene defined by SEQ ID NO: 22, said contacting being for a time sufficient for binding of the probe to the gene product; and

comparing a level binding of the probe to the sample with a level of probe binding to a control sample obtained from a control colon cell, wherein the control colon cell is of known cancerous state;

wherein an increased level of binding of the probe in the test colon cell sample relative to the level of binding in a control sample is indicative of the cancerous state of the test colon cell.

2. (Withdrawn) The method of claim 1, wherein the probe is a polynucleotide probe and the gene product is nucleic acid.

3. (Withdrawn) The method of claim 1, wherein the gene product is a polypeptide.

4. (Withdrawn) The method of claim 1, wherein the gene product is immobilized on an array.

5. (Withdrawn) The method of claim 1, wherein the probe is immobilized on an array.

6. (Currently amended) A method for assessing the phenotype of a colon cell comprising:

detecting expression of a gene product in a test colon cell sample, wherein the gene product is encoded by a gene defined by SEQ ID NO: 22; and

comparing a level of expression of the gene product in the test colon cell sample with a level of expression of the gene product in a control colon cell sample;

wherein a test colon cell sample with a an increase of at least 2-fold in the level of expression of the gene product increased at least 2-fold in the test colon cell sample as compared to the control colon cell sample is indicative of a colon cell with a cancerous phenotype in the colon cell.

7. (Currently amended) The method of claim 6, wherein expression of the gene product is by detecting a level of an RNA transcript in the test cell sample.

8. (Currently amended) The method of claim 6, wherein expression of the gene product is by detecting a level of a polypeptide in the test sample.

9-12. (Cancelled)

13. (Withdrawn) A method for assessing the tumor burden of a subject, the method comprising:

detecting a level of a differentially expressed gene product in a test sample from a subject suspected of or having a tumor, wherein the differentially expressed gene product is encoded by a gene defined by SEQ ID NO:22;

wherein detection of the level of the gene product in the test sample is indicative of the tumor burden in the subject.

14-22. (Cancelled)

23. (Currently amended) The method of claim 6, wherein a test colon cell sample with a an increase of at least 2.5-fold in the level of expression of the gene product increased at least 2.5-fold in the test colon cell sample as compared to the control colon cell sample is indicative of a colon cell with a cancerous phenotype in the colon cell.

24. (Currently amended) The method of claim 6, wherein ~~a test colon cell sample with a an increase of at least 5-fold in the level of expression of the gene product increased at least 5-fold in the test colon cell sample as compared to the control colon cell sample is indicative of a colon cell with a cancerous phenotype in the colon cell.~~
25. (Previously presented) The method of claim 7, wherein said detecting comprises contacting said test colon cell sample with a polynucleotide that specifically hybridizes to said RNA transcript.
26. (Previously presented) The method of claim 8, wherein said detecting comprises contacting said test colon cell sample with a probe specific for said polypeptide.
27. (Previously presented) The method of claim 26, wherein said probe is an antibody.
28. (Previously presented) The method of claim 27, wherein said antibody is detectably labeled.